MedTrace Logo

Ultrasound-Guided Rectus Sheath Block in Gynecological Single-Port Laparoscopy

NCT06862947 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-03-06

No results posted yet for this study

Summary

Title: Ultrasound-Guided Rectus Sheath Block in Gynecological Single-Port Laparoscopy

Brief Summary:

This study aims to evaluate the effects of preoperative ultrasound-guided bilateral rectus sheath block (RSB) on analgesic efficacy and recovery outcomes in patients undergoing gynecological single-port laparoscopy. The study is a prospective, randomized, double-blind, placebo-controlled trial involving 90 patients aged 18 to 65 years, with ASA I or II physical status, scheduled for single-port laparoscopic surgery lasting less than 2 hours. Participants are randomly assigned to either the RSB group or the placebo group, with 45 patients in each group. The RSB group receives bilateral RSB with 15 ml of 0.4% ropivacaine on each side, while the placebo group receives an equal volume of 0.9% saline. The primary outcome is postoperative pain assessed using the Visual Analog Scale (VAS) at multiple time points. Secondary outcomes include opioid consumption, effective activations of the analgesia pump, and postoperative recovery parameters such as time to mobilization and length of hospital stay. The study hypothesizes that preoperative ultrasound-guided bilateral RSB will significantly improve postoperative

Conditions

  • Gynecological Laparoscopy
  • Postoperative Pain
  • Rectus Sheath Block

Interventions

PROCEDURE

Rectus Sheath Block

Bilateral rectus sheath block performed under ultrasound guidance using 15 ml of 0.4% ropivacaine on each side

PROCEDURE

Placebo

Injection of 15 ml of 0.9% saline as a placebo under the same conditions as the experimental group.

Sponsors & Collaborators

  • Chengdu Jinjiang Maternity and Child Health Hospital

    lead OTHER

Principal Investigators

  • Fei Jia, BS · Chengdu Jinjiang District Women & Children Health Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-26
Primary Completion
2023-04-22
Completion
2024-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06862947 on ClinicalTrials.gov